[96a5a0]: / output / allTrials / identified / NCT04191382_identified.json

Download this file

829 lines (829 with data), 38.2 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
{
"info": {
"nct_id": "NCT04191382",
"official_title": "Phase 2 Window Study of Two Dose Levels of Amcenestrant [SAR439859] (SERD) Versus Letrozole in Newly Diagnosed Pre-operative Post-menopausal Patients With ER Positive, HER2 Negative Primary Breast Cancer",
"inclusion_criteria": "Healthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
"exclusion_criteria": "",
"miscellaneous_criteria": "Inclusion criteria :\n\n* Histological or cytological proven diagnosis of invasive breast adenocarcinoma.\n* Localized breast cancer eligible for upfront breast conservative surgery or upfront mastectomy: Stage I, Stage II or operable Stage III (excluded T4) as defined in American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th edition 2017.\n* Postmenopausal women as defined by one of the following:\n* Spontaneous cessation of menses greater than (>) 12 months.\n* or who had received hormonal replacement therapy but had discontinued the treatment and had follicle stimulating hormone (FSH) level in the postmenopausal range.\n* or with status post bilateral surgical oophorectomy.\n* or post bilateral ovarian ablation through pelvic radiotherapy.\n* Breast tumor size of at least 10 millimeters (mm) in greatest dimension measured by ultrasound.\n* Primary tumor had to be positive for Estrogen Receptors (ER+) and negative for HER2 (HER2-) receptor by immunohistochemistry.\n* Ki67 level of at least 15% at diagnosis from immunohistochemistry of the tumor.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n\nExclusion criteria:\n\n* Medical history or ongoing gastrointestinal disorders potentially affecting the absorption of SAR439859 or letrozole.\n* Participants unable to swallow normally and to take capsules or tablets.\n* Participants with known active hepatitis A, B, C infection; or hepatic cirrhosis.\n* Participant with any other cancer; adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or any other cancer from which the participant had been disease free for >3 years were allowed.\n* Evidence of metastatic spread by standard assessment according to local practice.\n* Treatment with strong Cytochrome P450 3A (CYP3A) inducers or drugs that had the potential to inhibit uridine diphosphate glucuronosyltransferase (UGT) within 2 weeks before first study treatment administration or 5 elimination half-lives whichever was longest.\n* Treatment with drugs that were sensitive substrates of P-glycoprotein (P-gp) or of breast cancer resistance protein (BCRP) within 2 weeks before first study treatment administration or 5 elimination half-lives whichever was longer.\n* Use of any investigational agent within 4 weeks prior to randomization.\n* Recent use of hormone replacement therapy (last dose less than or equal to [<=] 30 days prior to randomization).\n* Prior anti-cancer treatment was not allowed unless it was then completed at least 1 year prior to inclusion into this trial.\n* Previous systemic or local treatment for the new primary breast cancer currently under investigation (including surgery, radiotherapy, cytotoxic and endocrine treatments).\n* Inadequate hematological or renal function.\n* Prothrombin time/international normalized ratio (INR) >1.5 * upper limit of normal (ULN) or outside therapeutic range if received anticoagulation that would have had affected the prothrombin time/INR.\n* Any of the following abnormal liver function test results: Aspartate aminotransferase >1.5 * ULN; Alanine aminotransferase >1.5 * ULN; Total bilirubin >1.5 * ULN.\n* Participants were employees of the clinical study site or other individuals directly involved in the conduct of the study, or immediate family members of such individuals.\n* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial."
},
"inclusion_lines": [
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "female"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [],
"miscellaneous_lines": [
{
"line": "* Histological or cytological proven diagnosis of invasive breast adenocarcinoma.",
"criterions": [
{
"exact_snippets": "Histological or cytological proven diagnosis of invasive breast adenocarcinoma.",
"criterion": "invasive breast adenocarcinoma",
"requirements": [
{
"requirement_type": "diagnosis method",
"expected_value": [
"histological",
"cytological"
]
}
]
}
]
},
{
"line": "* Localized breast cancer eligible for upfront breast conservative surgery or upfront mastectomy: Stage I, Stage II or operable Stage III (excluded T4) as defined in American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th edition 2017.",
"criterions": [
{
"exact_snippets": "Localized breast cancer",
"criterion": "breast cancer",
"requirements": [
{
"requirement_type": "localization",
"expected_value": "localized"
}
]
},
{
"exact_snippets": "eligible for upfront breast conservative surgery or upfront mastectomy",
"criterion": "surgical eligibility",
"requirements": [
{
"requirement_type": "surgery type",
"expected_value": [
"breast conservative surgery",
"mastectomy"
]
}
]
},
{
"exact_snippets": "Stage I, Stage II or operable Stage III (excluded T4)",
"criterion": "cancer stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"Stage I",
"Stage II",
"operable Stage III"
]
},
{
"requirement_type": "exclusion",
"expected_value": "T4"
}
]
},
{
"exact_snippets": "as defined in American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th edition 2017",
"criterion": "cancer staging definition",
"requirements": [
{
"requirement_type": "reference",
"expected_value": "AJCC Cancer Staging Manual 8th edition 2017"
}
]
}
]
},
{
"line": "* Postmenopausal women as defined by one of the following:",
"criterions": [
{
"exact_snippets": "Postmenopausal women",
"criterion": "menopausal status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "postmenopausal"
}
]
}
]
},
{
"line": "* Spontaneous cessation of menses greater than (>) 12 months.",
"criterions": [
{
"exact_snippets": "Spontaneous cessation of menses greater than (>) 12 months.",
"criterion": "cessation of menses",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 12,
"unit": "months"
}
}
]
}
]
},
{
"line": "* or who had received hormonal replacement therapy but had discontinued the treatment and had follicle stimulating hormone (FSH) level in the postmenopausal range.",
"criterions": [
{
"exact_snippets": "received hormonal replacement therapy",
"criterion": "hormonal replacement therapy",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "discontinued the treatment",
"criterion": "hormonal replacement therapy",
"requirements": [
{
"requirement_type": "current status",
"expected_value": "discontinued"
}
]
},
{
"exact_snippets": "follicle stimulating hormone (FSH) level in the postmenopausal range",
"criterion": "FSH level",
"requirements": [
{
"requirement_type": "range",
"expected_value": "postmenopausal range"
}
]
}
]
},
{
"line": "* or with status post bilateral surgical oophorectomy.",
"criterions": [
{
"exact_snippets": "status post bilateral surgical oophorectomy",
"criterion": "bilateral surgical oophorectomy",
"requirements": [
{
"requirement_type": "status",
"expected_value": "post"
}
]
}
]
},
{
"line": "* or post bilateral ovarian ablation through pelvic radiotherapy.",
"criterions": [
{
"exact_snippets": "post bilateral ovarian ablation",
"criterion": "bilateral ovarian ablation",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "post"
}
]
},
{
"exact_snippets": "pelvic radiotherapy",
"criterion": "pelvic radiotherapy",
"requirements": [
{
"requirement_type": "method",
"expected_value": "radiotherapy"
}
]
}
]
},
{
"line": "* Breast tumor size of at least 10 millimeters (mm) in greatest dimension measured by ultrasound.",
"criterions": [
{
"exact_snippets": "Breast tumor size of at least 10 millimeters (mm) in greatest dimension measured by ultrasound.",
"criterion": "breast tumor size",
"requirements": [
{
"requirement_type": "size",
"expected_value": {
"operator": ">=",
"value": 10,
"unit": "mm"
}
}
]
}
]
},
{
"line": "* Primary tumor had to be positive for Estrogen Receptors (ER+) and negative for HER2 (HER2-) receptor by immunohistochemistry.",
"criterions": [
{
"exact_snippets": "Primary tumor had to be positive for Estrogen Receptors (ER+)",
"criterion": "Estrogen Receptors (ER)",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "positive"
}
]
},
{
"exact_snippets": "negative for HER2 (HER2-) receptor",
"criterion": "HER2 receptor",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "negative"
}
]
}
]
},
{
"line": "* Ki67 level of at least 15% at diagnosis from immunohistochemistry of the tumor.",
"criterions": [
{
"exact_snippets": "Ki67 level of at least 15%",
"criterion": "Ki67 level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">=",
"value": 15,
"unit": "%"
}
}
]
}
]
},
{
"line": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0-1",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 1,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "* Medical history or ongoing gastrointestinal disorders potentially affecting the absorption of SAR439859 or letrozole.",
"criterions": [
{
"exact_snippets": "Medical history or ongoing gastrointestinal disorders",
"criterion": "gastrointestinal disorders",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "potentially affecting the absorption of SAR439859 or letrozole",
"criterion": "absorption of SAR439859 or letrozole",
"requirements": [
{
"requirement_type": "effect",
"expected_value": "potentially affecting"
}
]
}
]
},
{
"line": "* Participants unable to swallow normally and to take capsules or tablets.",
"criterions": [
{
"exact_snippets": "Participants unable to swallow normally",
"criterion": "swallowing ability",
"requirements": [
{
"requirement_type": "ability",
"expected_value": false
}
]
},
{
"exact_snippets": "unable ... to take capsules or tablets",
"criterion": "ability to take capsules or tablets",
"requirements": [
{
"requirement_type": "ability",
"expected_value": false
}
]
}
]
},
{
"line": "* Participants with known active hepatitis A, B, C infection; or hepatic cirrhosis.",
"criterions": [
{
"exact_snippets": "known active hepatitis A",
"criterion": "hepatitis A infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "known active hepatitis ... B",
"criterion": "hepatitis B infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "known active hepatitis ... C",
"criterion": "hepatitis C infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "hepatic cirrhosis",
"criterion": "hepatic cirrhosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Participant with any other cancer; adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or any other cancer from which the participant had been disease free for >3 years were allowed.",
"criterions": [
{
"exact_snippets": "Participant with any other cancer",
"criterion": "other cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "adequately treated basal cell or squamous cell skin cancer",
"criterion": "basal cell or squamous cell skin cancer",
"requirements": [
{
"requirement_type": "treatment status",
"expected_value": "adequately treated"
}
]
},
{
"exact_snippets": "in situ cervical cancer",
"criterion": "in situ cervical cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "any other cancer from which the participant had been disease free for >3 years",
"criterion": "other cancer",
"requirements": [
{
"requirement_type": "disease-free duration",
"expected_value": {
"operator": ">",
"value": 3,
"unit": "years"
}
}
]
}
]
},
{
"line": "* Evidence of metastatic spread by standard assessment according to local practice.",
"criterions": [
{
"exact_snippets": "Evidence of metastatic spread",
"criterion": "metastatic spread",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Treatment with strong Cytochrome P450 3A (CYP3A) inducers or drugs that had the potential to inhibit uridine diphosphate glucuronosyltransferase (UGT) within 2 weeks before first study treatment administration or 5 elimination half-lives whichever was longest.",
"criterions": [
{
"exact_snippets": "Treatment with strong Cytochrome P450 3A (CYP3A) inducers",
"criterion": "treatment with strong CYP3A inducers",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "drugs that had the potential to inhibit uridine diphosphate glucuronosyltransferase (UGT)",
"criterion": "treatment with UGT inhibitors",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Treatment with drugs that were sensitive substrates of P-glycoprotein (P-gp) or of breast cancer resistance protein (BCRP) within 2 weeks before first study treatment administration or 5 elimination half-lives whichever was longer.",
"criterions": [
{
"exact_snippets": "Treatment with drugs that were sensitive substrates of P-glycoprotein (P-gp)",
"criterion": "treatment with P-glycoprotein (P-gp) substrates",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 2,
"unit": "weeks"
}
]
}
}
]
},
{
"exact_snippets": "Treatment with drugs that were sensitive substrates of ... breast cancer resistance protein (BCRP)",
"criterion": "treatment with breast cancer resistance protein (BCRP) substrates",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 2,
"unit": "weeks"
}
]
}
}
]
}
]
},
{
"line": "* Use of any investigational agent within 4 weeks prior to randomization.",
"criterions": [
{
"exact_snippets": "Use of any investigational agent within 4 weeks prior to randomization.",
"criterion": "use of investigational agent",
"requirements": [
{
"requirement_type": "time since last use",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Recent use of hormone replacement therapy (last dose less than or equal to [<=] 30 days prior to randomization).",
"criterions": [
{
"exact_snippets": "Recent use of hormone replacement therapy (last dose less than or equal to [<=] 30 days prior to randomization)",
"criterion": "hormone replacement therapy",
"requirements": [
{
"requirement_type": "recent use",
"expected_value": {
"operator": "<=",
"value": 30,
"unit": "days"
}
}
]
}
]
},
{
"line": "* Prior anti-cancer treatment was not allowed unless it was then completed at least 1 year prior to inclusion into this trial.",
"criterions": [
{
"exact_snippets": "Prior anti-cancer treatment was not allowed unless it was then completed at least 1 year prior to inclusion",
"criterion": "prior anti-cancer treatment",
"requirements": [
{
"requirement_type": "completion time",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "year"
}
}
]
}
]
},
{
"line": "* Previous systemic or local treatment for the new primary breast cancer currently under investigation (including surgery, radiotherapy, cytotoxic and endocrine treatments).",
"criterions": [
{
"exact_snippets": "Previous systemic or local treatment for the new primary breast cancer",
"criterion": "previous treatment for new primary breast cancer",
"requirements": [
{
"requirement_type": "treatment type",
"expected_value": [
"systemic",
"local"
]
}
]
},
{
"exact_snippets": "(including surgery, radiotherapy, cytotoxic and endocrine treatments)",
"criterion": "types of previous treatment",
"requirements": [
{
"requirement_type": "treatment type",
"expected_value": [
"surgery",
"radiotherapy",
"cytotoxic",
"endocrine"
]
}
]
}
]
},
{
"line": "* Inadequate hematological or renal function.",
"criterions": [
{
"exact_snippets": "Inadequate hematological ... function.",
"criterion": "hematological function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": false
}
]
},
{
"exact_snippets": "Inadequate ... renal function.",
"criterion": "renal function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": false
}
]
}
]
},
{
"line": "* Prothrombin time/international normalized ratio (INR) >1.5 * upper limit of normal (ULN) or outside therapeutic range if received anticoagulation that would have had affected the prothrombin time/INR.",
"criterions": [
{
"exact_snippets": "Prothrombin time/international normalized ratio (INR) >1.5 * upper limit of normal (ULN)",
"criterion": "prothrombin time/INR",
"requirements": [
{
"requirement_type": "comparison",
"expected_value": {
"operator": ">",
"value": 1.5,
"unit": "* ULN"
}
}
]
},
{
"exact_snippets": "outside therapeutic range if received anticoagulation",
"criterion": "prothrombin time/INR",
"requirements": [
{
"requirement_type": "therapeutic range",
"expected_value": "outside"
}
]
}
]
},
{
"line": "* Any of the following abnormal liver function test results: Aspartate aminotransferase >1.5 * ULN; Alanine aminotransferase >1.5 * ULN; Total bilirubin >1.5 * ULN.",
"criterions": [
{
"exact_snippets": "Aspartate aminotransferase >1.5 * ULN",
"criterion": "Aspartate aminotransferase",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 1.5,
"unit": "* ULN"
}
}
]
},
{
"exact_snippets": "Alanine aminotransferase >1.5 * ULN",
"criterion": "Alanine aminotransferase",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 1.5,
"unit": "* ULN"
}
}
]
},
{
"exact_snippets": "Total bilirubin >1.5 * ULN",
"criterion": "Total bilirubin",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 1.5,
"unit": "* ULN"
}
}
]
}
]
},
{
"line": "* Participants were employees of the clinical study site or other individuals directly involved in the conduct of the study, or immediate family members of such individuals.",
"criterions": [
{
"exact_snippets": "Participants were employees of the clinical study site",
"criterion": "employment status",
"requirements": [
{
"requirement_type": "employment",
"expected_value": "employee of the clinical study site"
}
]
},
{
"exact_snippets": "other individuals directly involved in the conduct of the study",
"criterion": "involvement in study",
"requirements": [
{
"requirement_type": "involvement",
"expected_value": "directly involved in the conduct of the study"
}
]
},
{
"exact_snippets": "immediate family members of such individuals",
"criterion": "relationship to study personnel",
"requirements": [
{
"requirement_type": "relationship",
"expected_value": "immediate family member"
}
]
}
]
},
{
"line": "* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.",
"criterions": [
{
"exact_snippets": "Sensitivity to any of the study interventions, or components thereof",
"criterion": "sensitivity to study interventions",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study",
"criterion": "drug or other allergy",
"requirements": [
{
"requirement_type": "contraindication",
"expected_value": true
}
]
}
]
}
],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": [
{
"line": "Inclusion criteria :",
"criterions": []
},
{
"line": "Exclusion criteria:",
"criterions": []
},
{
"line": "The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.",
"criterions": []
}
]
}